Skip to content

GLP-1s & incretins

Cagrilintide

A long-acting amylin analogue, mostly studied in combination with a GLP-1 agonist.

L4Strong humanInvestigationalIn clinical developmentModerate confidenceLast reviewed 2026-08-23
SC injection

Also known as: amylin analogue, component of combination therapy

Evidence passport

Last reviewed 2026-08-23

Evidence level
L4Strong human
Confidence
Moderate confidence
Human efficacy
65/100
Human safety
45/100
Regulatory status
Investigational
Development
In clinical development
Routes
SC injection
Evidence base
Includes human data
Furthest stage
Not established
Source curation
Source curation pending
Clinical maturity
Late-stage investigational, largely as combination therapy

Overview

Human evidence65/100
Preclinical evidence78/100
Human safety evidence45/100

Clinical maturity: Late-stage investigational, largely as combination therapy

Routes & formulations

Studied / approved routes

SC injection

Clinical trials use subcutaneous injection; there is no approved formulation of any kind.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

In clinical developmentFurthest stage not established in our curated record

Late-stage investigational programme, largely in combination with semaglutide; the precise current stage is not established in our curated record.

What it is

A synthetic long-acting version of amylin, a hormone co-secreted with insulin that promotes satiety and slows gastric emptying through a different route from GLP-1.

What people claim

  • Adds weight loss on top of GLP-1 therapy
  • Different satiety pathway, additive effect

What the evidence actually says

Human trials support additional weight reduction when combined with a GLP-1 agonist, which is mechanistically plausible. Standalone long-term data are thinner, and the regulatory story is still being written.

Human evidence

  • Randomised trials of the combination showing additive weight reduction versus GLP-1 alone.
  • Dose-ranging monotherapy studies.

Preclinical evidence

  • Amylin receptor pharmacology and rodent satiety models.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Amylin/calcitonin receptor signalling in the area postrema reduces meal size.
  • Complementary rather than duplicative to GLP-1 signalling.

Safety and unknowns

  • Gastrointestinal effects, injection-site reactions.
  • Long-term safety of chronic amylin agonism remains under study.

Cancer relevance

No established human signal

No established human cancer signal. Not a primary safety question for this compound.

Regulatory status

Investigational. Studied alone and as part of a fixed-dose combination with semaglutide (CagriSema, in Phase 3); not a generally approved standalone medicine.

Evidence grade

L4Strong humanModerate confidence

Solid controlled human trials, though not yet definitive or fully replicated.

What would change our rating?

  • Phase 3 readouts and a regulatory decision on the combination.

References and sources

Source curation pending
  • To be curatedSources to be curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

  1. 2026-06-18

    Baseline entry: added as combination-therapy candidate with moderate confidence.

    L4Strong humanBaseline entry
    Additive weight reduction in combination trials is supported. Standalone long-term evidence remains limited.